John Michael Erickson

US Patent:

7087373, Aug 8, 2006

Filed:

Jun 5, 2002

Appl. No.:

10/161613

Inventors:

Dong Xie - Germantown MD, US
Wei Cao - Centereach NY, US
John W. Erickson - Frederick MD, US

Assignee:

Tibotec Pharmaceuticals Ltd. - County Cork

International Classification:

C12Q 1/37
G01N 33/53
G01N 33/48

US Classification:

435 4, 435 71, 435 23, 702 19

Abstract:

Methods for isothermal titration calorimetry analysis of the binding affinity of protease inhibitors to plasma proteins. A method that can quantitatively calculate free drug concentrations of protease inhibitors in human plasma, as well as a method to calculate therapeutic amounts and dosage regimens. Furthermore, the present invention provides a method that can calculate the effect of plasma proteins on the antiviral activity (EC50 values) of protease inhibitors from their binding affinities to plasma proteins. The present invention provides as well a method that can evaluate the in vivo anti-HIV efficacy of PIs in human plasma.

US Patent:

7151163, Dec 19, 2006

Filed:

Apr 28, 2004

Appl. No.:

10/833304

Inventors:

John W. Erickson - Potomac MD, US
Abelardo Silva - Ellicott City MD, US

Assignee:

Sequoia Pharmaceuticals, Inc. - Gaithersburg MD

International Classification:

C07K 14/165
C07K 17/00
A61K 39/215
A61K 39/385

US Classification:

530363, 514 12, 4241861, 42419611, 4242211, 4241921

Abstract:

The invention provides compositions and methods that are useful for preventing and treating a coronavirus infection in a subject. More specifically, the invention provides peptides and conjugates and pharmaceutical compositions containing those peptides and conjugates that block fusion of a coronavirus, such as the SARS virus, to a target cell. This blocking mechanism prevents or treats a coronavirus infection, such as a SARS infection, in a subject, such as a human subject.

US Patent:

7285566, Oct 23, 2007

Filed:

Jan 7, 2003

Appl. No.:

10/500888

Inventors:

John W. Erickson - Potomac MD, US
Michael Eissenstat - Frederick MD, US
Abelardo Silva - Ellicott City MD, US
Sergei Gulnik - Frederick MD, US

International Classification:

A61K 31/404
C07D 209/30

US Classification:

514367, 514375, 548159, 548222

Abstract:

Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

US Patent:

7739671, Jun 15, 2010

Filed:

Aug 12, 2005

Appl. No.:

11/203590

Inventors:

Michael G. Hinchey - Bowie MD, US
James L. Rash - Davidsonville MD, US
John D. Erickson - Midland TX, US
Denis Gracinin - Blacksburg VA, US
Christopher A. Rouff - Beltsville MD, US

Assignee:

The United States of America as represented by the Administrator of the National Aeronautics and Space Administration - Washington DC

International Classification:

G06F 9/44
G06F 9/45
G06F 17/00
G06N 5/04
G06N 5/02

US Classification:

717136, 717117, 717106, 717146, 706922, 706 56, 706 60, 706 46, 706 47

Abstract:

Systems, methods and apparatus are provided through which in some embodiments an informal specification is translated without human intervention into a formal specification. In some embodiments the formal specification is a process-based specification. In some embodiments, the formal specification is translated into a high-level computer programming language which is further compiled into a set of executable computer instructions.

US Patent:

7752608, Jul 6, 2010

Filed:

Aug 12, 2005

Appl. No.:

11/203586

Inventors:

Michael G. Hinchey - Bowie MD, US
James L. Rash - Davidsonville MD, US
John D. Erickson - Midland TX, US
Denis Gracinin - Blacksburg VA, US
Christopher A. Rouff - Beltsville MD, US

Assignee:

The United States of America as represented by the Administrator of the National Aeronautics and Space Administration - Washington DC

International Classification:

G06F 9/45
G06F 9/44
G06F 17/00
G06N 5/04
G06N 5/02

US Classification:

717136, 717107, 717146, 717106, 717117, 706 56, 706 60, 706 46, 706 47

Abstract:

Systems, methods and apparatus are provided through which in some embodiments, domain knowledge is translated into a knowledge-based system. In some embodiments, a formal specification is derived from rules of a knowledge-based system, the formal specification is analyzed, and flaws in the formal specification are used to identify and correct errors in the domain knowledge, from which a knowledge-based system is translated.

US Patent:

20050208678, Sep 22, 2005

Filed:

Sep 27, 2002

Appl. No.:

10/490716

Inventors:

Dong Xie - Germantown MD, US
John Erickson - Frederick MD, US
Paul Grulich - Gaithersburg MD, US

International Classification:

G01N033/561
G06F019/00
G01N033/48
G01N033/50

US Classification:

436516000, 702019000

Abstract:

Methods of identifying a fusion inhibitor and inhibitors of gp41-mediated membrane fusion are disclosed. The methods comprise, for example, providing a first helical polypeptide comprising a sequence of IQN17 (SEQ ID NO: 1); providing a second helical polypeptide of 34 or less than 34 amino acids comprising the amino acid sequence W-X1-X2-W-X3-X4-X5-I, wherein X1, X2, X3, X4, and X5 are each independently chosen from any amino acid except proline; measuring, by capillary zone electrophoresis, the degree of complex formation between these peptides; and comparing the measured degree of complex formation to the degree in the presence of a test composition.

US Patent:

20060205002, Sep 14, 2006

Filed:

May 5, 2006

Appl. No.:

11/429481

Inventors:

Dong Xie - Germantown MD, US
Wei Cao - Centereach NY, US
John Erickson - Frederick MD, US

Assignee:

Tibotec Pharmaceuticals Ltd. - Little Island

International Classification:

C12Q 1/70
C12Q 1/68

US Classification:

435006000, 435005000

Abstract:

Methods for isothermal titration calorimetry analysis of the binding affinity of protease inhibitors to plasma proteins. A method that can quantitatively calculate free drug concentrations of protease inhibitors in human plasma, as well as a method to calculate therapeutic amounts and dosage regimens. Furthermore, the present invention provides a method that can calculate the effect of plasma proteins on the antiviral activity (EC50 values) of protease inhibitors from their binding affinities to plasma proteins. The present invention provides as well a method that can evaluate the in vivo anti-HIV efficacy of PIs in human plasma.

US Patent:

20070185027, Aug 9, 2007

Filed:

Nov 9, 2006

Appl. No.:

11/557983

Inventors:

John Erickson - Potomac MD, US
Abelardo Silva - Ellicott City MD, US

Assignee:

SEQUOIA PHARMACEUTICALS, INC. - GAITHERSBURG MD

International Classification:

A61K 38/16
A61K 38/10
A61K 38/08
C07K 7/08
C07K 7/06
C07K 14/165

US Classification:

514012000, 530324000, 530325000, 530326000, 530327000, 530328000, 530329000, 530330000, 514013000, 514014000, 514015000, 514016000, 514017000

Abstract:

The invention provides compositions and methods that are useful for preventing and treating a coronavirus infection in a subject. More specifically, the invention provides peptides and conjugates and pharmaceutical compositions containing those peptides and conjugates that block fusion of a coronavirus, such as the SARS virus, to a target cell. This blocking mechanism prevents or treats a coronavirus infection, such as a SARS infaction, in a subject, such as a human subject.